 SOMERSET, N.J.--BUSINESS WIRE--- LEGN biotech--Legend Biotech Corporation NASDAQ: LEGN Legend Biotech, a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today reported its unaudited financial results for the three months and year ended December 31, 2020. This was a defining year for Legend Biotech, as we achieved important pipeline advancements and completed our initial public offering and Nasdaq listing 